Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 1, 2014, Pages 403-408

  Kumari, Shraddha ^a,b   Wälchli, Sébastien ^a,b   Fallang, Lars Egil ^a   Yang, Weiwen ^a,b   Lund Johansen, Fridtjof ^a,b   Schumacher, Ton N ^b,c   Olweus, Johanna ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; DIFFERENTIATION ANTIGEN; EPITOPE; HLA A2 ANTIGEN; MYELOPEROXIDASE; POLYMER; TUMOR ANTIGEN;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; TARGET CELL;

ALGORITHMS; ANTIGEN PRESENTATION; ANTIGENS, CD20; ANTIGENS, NEOPLASM; AUTOANTIGENS; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HL-60 CELLS; HLA-A2 ANTIGEN; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MASS SPECTROMETRY; NEOPLASMS; PEPTIDES; PEROXIDASE; PROTEIN BINDING; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84891938083     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1306549111     Document Type: Article

References (42)

1. Andersen RS, et al. (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72(7): 1642-1650.
2. Admon A, Bassani-Sternberg M (2011) The Human Immunopeptidome Project, a suggestion for yet another postgenome next big thing. Mol Cell Proteomics 10(10): 011833.
3. Rammensee HG, Falk K, Rötzschke O (1993) Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11: 213-244.
4. Stevanovi-c S, Schild H (1999) Quantitative aspects of T cell activation-Peptide generation and editing by MHC class I molecules. Semin Immunol 11(6): 375-384.
5. Hassan C, et al. (2013) The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics 12(7): 1829-1843.
6. Nielsen M, et al. (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2(8):e796.
7. de Verteuil D, Granados DP, Thibault P, Perreault C (2012) Origin and plasticity of MHC I-associated self peptides. Autoimmun Rev 11(9): 627-635.
8. Stronen E, et al. (2009) Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells. Scand J Immunol 69(4): 319-328.
9. Wilde S, et al. (2009) Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 114(10): 2131-2139.
10. Shiina T, Hosomichi K, Inoko H, Kulski JK (2009) The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 54(1): 15-39.
11. Kessler JH, Melief CJ (2007) Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21(9): 1859-1874.
12. Amir AL, et al. (2011) Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood 118(26): 6733-6742.
13. Hadrup SR, et al. (2009) Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 6(7): 520-526.
14. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184(2): 465-472.
15. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ (1998) Generation of human tumorreactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 28(1): 193-200.
16. Savage P, et al. (2004) Use of B cell-bound HLA-A2 class I monomers to generate highavidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103(12): 4613-4615.
17. Gao L, Downs AM, Stauss HJ (2005) Immunotherapy with CTL restricted by nonself MHC. Methods Mol Med 109: 215-228.
18. Felix NJ, et al. (2007) Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 8(4): 388-397.
19. Housset D, Malissen B (2003) What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity? Trends Immunol 24(8): 429-437.
20. Udaka K, Tsomides TJ, Eisen HN (1992) A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69(6): 989-998.
21. Krönig H, et al. (2009) Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 125(3): 649-655.
22. Abrahamsen IW, et al. (2012) T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. Int J Cancer 130(8): 1821-1832.
23. Abrahamsen IW, et al. (2010) Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 24(11): 1901-1909.
24. Guimezanes A, et al. (2001) Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: Distinct characteristics correlated with CD8 dependence. Eur J Immunol 31(2): 421-432.
25. Mazza C, et al. (2007) How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides? EMBO J 26(7): 1972-1983.
26. Leisegang M, et al. (2010) MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 120(11): 3869-3877.
27. Falkenburg WJ, et al. (2011) Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity. J Immunol 187(5): 2824-2833.
28. Stanislawski T, et al. (2001) Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2(10): 962-970.
29. Engelhard VH, Brickner AG, Zarling AL (2002) Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol Immunol 39(3-4): 127-137.
30. Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12): 4371-4383.
31. Cooper LJ (2010) Off-the-shelf T-cell therapy. Blood 116(23): 4741-4743.
32. Barker JN, et al. (2010) Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 116(23): 5045-5049.
33. Wynn RF, et al. (2005) Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol 6(5): 344-346.
34. Haque T, et al. (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360(9331): 436-442.
35. Haque T, et al. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 110(4): 1123-1131.
36. Melenhorst JJ, et al. (2010) Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116(22): 4700-4702.
37. Schumacher TN (2002) T-cell-receptor gene therapy. Nat Rev Immunol 2(7): 512-519.
38. Morgan RA, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796): 126-129.
39. Robbins PF, et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NYESO-1. J Clin Oncol 29(7): 917-924.
40. Lundegaard C, et al. (2008) NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36(Web Server Issue):W509-12.
41. Toebes M, et al. (2006) Design and use of conditional MHC class I ligands. Nat Med 12(2): 246-251.
42. Wälchli S, et al. (2011) A practical approach to T-cell receptor cloning and expression. PLoS ONE 6(11):e27930.